123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients

NCT ID: NCT00586950

Last Updated: 2011-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-06-30

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this multi-center study is to determine the applicability of BMIPP to diagnosing cardiac disease and to predicting the outcome of patients on hemodialysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Disease Fatty Acids, Unsaturated Radioisotopes Hemodialysis Single Photon Emission Computed Tomography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypertension
* Diabetes mellitus
* Hyperlipidemia
* Obliterative arteriosclerosis in the lower extremities
* Smoker
* Family history of juvenile coronary artery disease
* History of ischemic stroke
* History of heart failure requiring hospitalization
* Within 3 months after initiation of hemodialysis therapy
* Dialysis hypotension

Exclusion Criteria

* Peritoneal dialysis
* Severe valvular disorder requiring treatment
* Diagnosis of hypertrophic cardiomyopathy(HCM) or dilated cardiomyopathy(DCM) before start of dialysis
* History of revascularization(PCI, CABG) or prior diagnosis of myocardial infarction
* Hypersensitivity to BMIPP or its analogue
* Judged unsuitable for the study for any other reasons by physicians.
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Toho University Ohashi Medical Center

UNKNOWN

Sponsor Role collaborator

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hokkaido Cardiovascular Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kenjiro Kikuchi, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Asahikawa Medical College

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Toho University Ohashi Medical Center

Meguro-ku, Tokyo, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UHA_CAD05-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.